New data on compounds in Basilea's anti-infective portfolio
(Thomson Reuters ONE) -
Basilea Pharmaceutica AG / New data on compounds in Basilea's anti-infective portfolio processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Basel, Switzerland, April 13, 2010 - Basilea Pharmaceutica Ltd. announces that
new data on the antibacterial compounds BAL30072 and ceftobiprole as well as the
antifungal drug isavuconazole were presented at the European Congress of
Clinical Microbiology and Infectious Disease (ECCMID) in Vienna. Basilea's
innovative and balanced anti-infective portfolio addresses priority concerns in
the treatment of serious infections.
Multi-resistant Gram-negative and Gram-positive bacteria are appearing with
increasing frequency in hospitals around the world and are causing a growing
therapeutic problem. Infections caused by multi-resistant bacilli have been
associated with prolonged hospital stays, higher healthcare costs and increased
mortality, particularly when initial antibiotic therapy does not provide
coverage of the causative pathogen.
BAL30072 - potent activity against multi-resistant Gram-negative bacteria
BAL30072 is a novel siderophore sulfactam antibiotic. Its unique pattern of
penicillin-binding-protein inhibition and its bactericidal mode of action confer
potent in-vitro and in-vivo activity against Gram-negative bacteria. Pathogens
such as Pseudomonas spp. and Acinetobacter spp. as well as the enterobacteria
Escherichia coli and Klebsiella pneumoniae are increasingly multi-resistant and
difficult-to-treat Gram-negative "superbugs". BAL30072 overcomes most mechanisms
of resistance to currently marketed beta-lactam antibiotics found in these
bacilli.
New research data presented at ECCMID by Miriagou and co-authors show that
BAL30072 demonstrates in-vivo efficacy against clinical metallo-beta-lactamase
producing isolates of E. coli and K. pneumoniae, resistant to several
antibiotics (poster P 1240). Furthermore, data from Carmeli and co-authors
showing BAL30072's strong in-vitro and in-vivo activity against
extended-spectrum-beta-lactamase producing E. coli was selected for an oral
presentation at ECCMID's "New antibacterial agents" session (O 376).
BAL30072 has previously been shown to have potent antibacterial activity in
vitro against multi-resistant Gram-negative bacteria, including
carbapenem-resistant strains. New in-vivo data demonstrate that
co-administration with meropenem enhances BAL30072's activity against resistant
Gram-negative bacteria (E. coli, K. pneumoniae), including strains that are not
susceptible to BAL30072 and meropenem as single agent, respectively (P 1240).
Basilea expects to initiate a phase I clinical development program for the
investigation of BAL30072 in humans in the second half of 2010.
Ceftobiprole - preserves human intestinal flora
Ceftobiprole is a broad-spectrum cephalosporin antibiotic exhibiting activity
against a wide spectrum of Gram-positive bacteria, including the 'superbug'
methicillin-resistant Staphylococcus aureus (MRSA) and penicillin-resistant
Streptococcus pneumoniae as well as many clinically important Gram-negative
bacteria, including Pseudomonas spp. Broad-spectrum antibiotic treatment
frequently negatively impacts the normal intestinal microflora.
As a result, it may facilitate colonization by new potentially pathogenic
strains or enable microorganisms already present in the normal intestinal flora
to develop resistance. Panagiotidis and co-authors presented new data showing
that ceftobiprole has no significant impact on intestinal flora of healthy
volunteers (P 1226).
Oral presentation on BAL30072 at ECCMID
BAL30072, a new sulfactam with excellent in vitro and in vivo activity against
Escherichia coli producing extended-spectrum beta-lactamases. - S.
Navon-Venezia, O. Hermesh, B. Kuzmenko, M. Page, Y. Carmeli; O 376
Posters on BAL30072 displayed at ECCMID
Efficacy of BAL30072, alone and combined with meropenem, against VIM-producing
enterobacteria in a murine thigh infection model. - V. Miriagou, C.
Papagiannitsis, S. Kotsakis, A. Zioga, E. Siatravani, A. Loli, E. Tzelepi, L.
Tzouvelekis, M. Donzelli, J. Spickermann, M. Page; P 1240
The role of iron transport in the activity of the siderophore sulfactam BAL30072
against Pseudomonas aeruginosa. - M. Page, C. Müller, B. Hofer, E. Desarbre, J.
Dreier, F. Vidal; P 1241
Oral presentation on ceftobiprole at ECCMID
In vitro synergism between ceftobiprole and vancomycin against
methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. -
J.M. Entenza, J. Vouillamoz, A. Bizzini, M. Giddey, J. Bille, P. Moreillon; O 39
Posters on ceftobiprole displayed at ECCMID
Trends in ceftobiprole susceptibility among 2001-2008 consecutive
methicillin-resistant Staphylococcus aureus blood isolates. - Y. Golan, L.
McDermott, D.R. Snydman; P 939
Effect of ceftobiprole on the normal human intestinal microflora. - G.
Panagiotidis, T. Bäckström, C. Asker-Hagelberg, M. Rashid, A. Weintraub, C.E.
Nord; P 1226
Susceptibility of Gram-negative pathogens to ceftobiprole, ceftazidime and
cefepime isolated from centres in Austria, Germany and Switzerland. - H.
Seifert, S. Gatermann, W. Pfister, C. Poehlmann, S. Huhulescu, K. Muehlemann, J.
Laeuffer, S. Decker-Burgard, M. Cassettari, I. Morrissey; P 1269
Ceftobiprole activity when tested against clinical bacterial pathogens from
Europe, 2009. - D. Farrell, G. Moet, H. Sader, S. Putnam, R. Jones; P 1875
Posters on isavuconazole displayed at ECCMID
Antifungal susceptibility of yeasts isolated from patients with fungaemia:
comparison of the E-test on direct blood samples and CLSI M27-A3. - J. Guinea,
S. Recio, P. Escribano, T. Peláez, M. Torres-Narbona, M. Rodríguez-Créixems, C.
Sánchez-Carrillo, E. Bouza; P 838
Can isavuconazole MICs for yeasts be read after 24 hours of incubation? - J.
Guinea, P. Escribano, S. Recio, T. Peláez, E. Bouza; P 839
In vitro activity of isavuconazole against clinical non-Candida yeast isolates
determined by E-test and CLSI M27-A3. - J. Guinea, S. Recio, P. Escribano, T.
Peláez, E. Bouza; P 840
For further information please visit www.congrex.ch/ECCMID2010
About Basilea
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on
the SIX Swiss Exchange (SIX:BSLN). Its integrated research and development
operations are currently focused on antibiotics and antifungals, as well as on
the development of dermatology and oncology drugs, all areas in which the
medical challenge of rising resistance or non-response to current treatment
options is commonly encountered. Basilea's products are targeted to satisfy high
medical and patient needs in the hospital and specialty care setting.
The company owns a broad and diversified portfolio. Basilea is marketing
Toctino® (alitretinoin), for the treatment of severe chronic hand eczema, in
Denmark, France, Germany, Switzerland and the United Kingdom. The drug is
approved in ten additional European countries as well as in Canada and has been
recommended for approval in 12 further European countries. Furthermore, a phase
III clinical trial on alitretinoin for the treatment of severe chronic hand
eczema is ongoing in the U.S. Basilea has entered into a license, co-development
and co-promotion agreement with Astellas Pharma Inc. for its phase III compound
isavuconazole for the treatment of life-threatening invasive fungal infections
on a worldwide basis, including an option for Japan. Full rights to a third
late-stage product, ceftobiprole for the treatment of potentially
life-threatening resistant bacterial infections, will be transferred from Cilag
GmbH International, a Johnson & Johnson company, back to Basilea.
Disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition, performance
or achievements of Basilea Pharmaceutica Ltd. to be materially different from
any future results, performance or achievements expressed or implied by such
forward-looking statements. Basilea Pharmaceutica Ltd. is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new information,
future events or otherwise.
For further information, please contact:
+----------------------------------------+-------------------------------------+
|Media Relations |Investor Relations |
+----------------------------------------+-------------------------------------+
|Adesh Kaul |Barbara Zink, Ph.D., MBA |
|Head Public Relations & |Head Corporate Development |
|Corporate Communications | |
|+41 61 606 1460 |+41 61 606 1233 |
|media_relations(at)basilea.com |investor_relations(at)basilea.com |
|
+----------------------------------------+-------------------------------------+
This press release can be downloaded from www.basilea.com
The press release can also be downloaded from the following link:
[HUG#1402786]
--- End of Message ---
Basilea Pharmaceutica AG
Grenzacherstrasse 487
P.O Box Basel Switzerland
Press release (PDF): http://hugin.info/134390/R/1402786/357244.pdf
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 13.04.2010 - 01:15 Uhr
Sprache: Deutsch
News-ID 1012744
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Basel
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 84 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"New data on compounds in Basilea's anti-infective portfolio
"
steht unter der journalistisch-redaktionellen Verantwortung von
Basilea Pharmaceutica AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
